↓ Skip to main content

Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine

Overview of attention for article published in Journal of Nuclear Medicine, February 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine
Published in
Journal of Nuclear Medicine, February 2014
DOI 10.2967/jnumed.113.132761
Pubmed ID
Authors

Rebecca A. Herbertson, Niall C. Tebbutt, Fook-Thean Lee, Sanjeev Gill, Bridget Chappell, Tina Cavicchiolo, Tim Saunder, Graeme J. O’Keefe, Aurora Poon, Sze Ting Lee, Roger Murphy, Wendie Hopkins, Fiona E. Scott, Andrew M. Scott, Herbertson RA, Tebbutt NC, Lee FT, Gill S, Chappell B, Cavicchiolo T, Saunder T, O'Keefe GJ, Poon A, Lee ST, Murphy R, Hopkins W, Scott FE, Scott AM, R. A. Herbertson, N. C. Tebbutt, F.-T. Lee, S. Gill, B. Chappell, T. Cavicchiolo, T. Saunder, G. J. O'Keefe, A. Poon, S. T. Lee, R. Murphy, W. Hopkins, F. E. Scott, A. M. Scott

Abstract

huA33 is a humanized antibody that targets the A33 antigen, which is highly expressed in intestinal epithelium and more than 95% of human colon cancers but not other normal tissues. Previous studies have shown huA33 can target and be retained in a metastatic tumor for 6 wk but eliminated from normal colonocytes within days. This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer. The primary objective was safety and tolerability of the combination of capecitabine and (131)I-huA33. Pharmacokinetics, biodistribution, immunogenicity, and tumor response were also assessed.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 35%
Professor > Associate Professor 3 18%
Other 2 12%
Student > Postgraduate 2 12%
Researcher 1 6%
Other 2 12%
Unknown 1 6%
Readers by discipline Count As %
Medicine and Dentistry 8 47%
Agricultural and Biological Sciences 2 12%
Immunology and Microbiology 1 6%
Physics and Astronomy 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Other 0 0%
Unknown 4 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2014.
All research outputs
#6,213,631
of 8,594,787 outputs
Outputs from Journal of Nuclear Medicine
#1,314
of 2,304 outputs
Outputs of similar age
#108,789
of 180,149 outputs
Outputs of similar age from Journal of Nuclear Medicine
#40
of 96 outputs
Altmetric has tracked 8,594,787 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,304 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,149 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.